Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sarilumab + conventional synthetic disease-modifying anti-rheumatic drugs
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Sarilumab + conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is a combination therapy used for the treatment of moderate-to-severe rheumatoid arthritis. Sarilumab is a human monoclonal antibody that inhibits both soluble and membrane-bound interleukin-6 receptor (IL-6R), blocking IL-6–mediated signaling and thereby reducing inflammation. csDMARDs are small-molecule immunosuppressive agents (including methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) that generally suppress immune function through a variety of mechanisms but do not target specific cytokines or immune cells. The combination is indicated for patients with rheumatoid arthritis who have had inadequate response or intolerance to anti-TNF agents, with the goal of reducing disease activity, improving physical function, and slowing radiographic progression[1][3][5].
- Brand names
- Kevzara
- Other names
- sarilumab + DMARDssarilumab + methotrexatesarilumab + conventional synthetic DMARDssarilumab + csDMARDs
02
Targets
IL-6R (Interleukin-6 receptor subunit alpha)
Beyond the preview
Go deeper on sarilumab + conventional synthetic disease-modifying anti-rheumatic drugs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sarilumab + conventional synthetic disease-modifying anti-rheumatic drugs.